










Cy is a phenyl, cyclohexyl, indanyl, 2,3-dihydrobenzofuranyl or tetrahydroquinoliny group, each optionally substituted with one, two, or three substituent groups independently selected from -Cl, -F, C₁₋₃alkyl, oxo and CN; and









R¹ and R² are independently selected from H, C₁₋₃alkyl, hydroxyC₁₋₃alkyl, -CH₂NHC(O)OC₁₋₄alkyl, -C(O)N(C₁₋₄-alkyl)₂ and -CH₂OC(O)C₁₋₄alkyl;









or a salt thereof.









In another aspect, there is provided a compound selected from the group consisting of
















2		26	
3		27	
4		28	
5		29 A	

6		29 B	
7		30	
8		31	
9		32	

10		33	
11		34	
12		35	
13		36	


14		37	
15		38	
16		39	
17		40	

18		41	
19		42	
20		43	
21		44	


22		45	
23		46	
24			

and the pharmaceutically acceptable salts thereof.


In another aspect, there is provided a compound that is




In another aspect, there is provided a compound that is




In another aspect, there is provided a compound that is




In another aspect, there is provided a compound that is




In another aspect, there is provided a compound that is




In another aspect, there is provided a compound that is




In another aspect, there is provided a compound that is




In another aspect, there is provided a compound that is



In another aspect, there is provided a compound that is



In another aspect, there is provided a compound that is




In another aspect, there is provided a pharmaceutical composition comprising a compound as defined herein and a pharmaceutically acceptable excipient or carrier.

In another aspect, there is provided a compound as defined herein for use as a medicament.

In another aspect, there is provided use of a compound as defined herein in the manufacture of a medicament for the treatment of a disease or disorder that can be alleviated by inhibition of aldosterone synthase selected from diabetic nephropathy, glomerulosclerosis, glomerulonephritis, IGA nephropathy, nephritic syndrome focal segmental glomerulosclerosis (FSGS), hypertension, pulmonary arterial hypertension, Conn's syndrome, systolic heart failure, diastolic heart failure, left ventricular dysfunction, left ventricular stiffness and fibrosis, left ventricular filing abnormalities, arterial stiffness, atherosclerosis and cardiovascular morbidity associated with primary or secondary hyperaldosteronism, adrenal hyperplasia and primary and secondary hyperaldosteronism.


DETAILED DESCRIPTION OF THE INVENTION

In an embodiment of the invention, there are provided compounds of the formula I



What is claimed is:

1. A compound of the formula I



I

wherein:

Cy is a phenyl, cyclohexyl, indanyl, 2,3-dihydrobenzofuranyl or tetrahydroquinoliny group, each optionally substituted with one, two, or three substituent groups independently selected from -Cl, -F, C₁₋₃alkyl, oxo and CN; and

R¹ and R² are independently selected from H, C₁₋₃alkyl, hydroxyC₁₋₃alkyl, -CH₂NHC(O)OC₁₋₄alkyl, -C(O)N(C₁₋₄-alkyl)₂ and -CH₂OC(O)C₁₋₄alkyl;

or a salt thereof.

2. The compound of formula I according to claim 1, wherein:

Cy is phenyl optionally substituted with one, two, or three substituent groups independently selected from -Cl, -F, C₁₋₃alkyl and CN.

3. The compound of formula I according to claims 1 or 2 wherein:

Cy is phenyl substituted with CN and optionally substituted with one or two additional groups independently selected from -Cl, -F and C₁₋₃alkyl;

R¹ is -CH₃; and

R² is -CH₃ or -CH₂OH.

4. The compound according to any of claims 1 to 3, wherein:

R² is -CH₂OH.


5. The compound according to any of claims 1 to 3, wherein:

R² is -CH₃.


6. A compound selected from the group consisting of

7. The compound according to claim 6 selected from the group consisting of compound numbers 1-11, 13, 15, 18, 19, 22, 23, 26, 28, 29A, 29B, 30-33, 35, 39, 41, 42, 45 and 46.


8. A compound that is




9. A compound that is




10. A compound that is




11. A compound that is




12. A compound that is




13. A compound that is




14. A compound that is




15. A compound that is



16. A compound that is



17. A compound that is



18. A pharmaceutically acceptable salt of a compound according to any of claims 1 to 17.

19. A pharmaceutical composition comprising a compound according to any of claims 1 to 18 and a pharmaceutically acceptable excipient or carrier.

20. A compound according to any of claims 1 to 18 for use as a medicament.